Piet Wigerinck, Galapagos

Gala­pa­gos CSO hits the ex­it as the biotech looks to pick up the pieces af­ter FDA's fil­go­tinib re­jec­tion

Months af­ter Gala­pa­gos cut away broad swaths of its pipeline fol­low­ing a re­jec­tion for Gilead-part­nered rheuma­toid arthri­tis drug fil­go­tinib, the biotech will now say good­bye to its long­time chief sci­en­tif­ic of­fi­cer as it con­sid­ers its op­tions mov­ing ahead.

Piet Wiger­inck will step down from his role lat­er this year, the com­pa­ny an­nounced on Tues­day. Wiger­inck joined in 2008 as the SVP of de­vel­op­ment, and be­came the CSO in 2012. He over­saw the dis­cov­ery of nov­el tar­gets through to clin­i­cal proof-of-con­cept stud­ies, led the first clin­i­cal re­search in healthy vol­un­teers and was re­spon­si­ble for two Phase II pro­grams for fil­go­tinib, a JAK in­hibitor.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.